14 related news articles for Lupus

  • Genetic changes identified as key to childhood lupus

    Hudson Institute researcher Professor Seth Masters, working with colleagues at China’s Guangzhou Women and Children’s Medical Center, has identified a specific genetic variant which contributes to the development of childhood-onset lupus.…  Read more

    Professor Seth Masters researching Childhood lupus
  • Better treatments sooner: Hudson unveils RNAte Platform

    Hudson Institute of Medical Research today officially unveiled its world-first RNAte platform that could see vaccines and therapeutic treatments developed faster by being able to rapidly assess their potential inflammation side effects, right here in Victoria.…  Read more

    Natalia Sampaio In the lab of the RNAte Platform at Hudson Institute
  • Searching for clues to how RNA triggers the immune system

    A young Melbourne scientist will spend the next three years advancing exiting new mRNA research to unlock the secrets to how RNA triggers the immune system to fight infection.…  Read more

    Dr Natália Sampaio from the Regulation of Interferon and Innate Signalling Research Group
  • Soy molecule may lead to new anti-inflammatory drug

    A naturally occurring molecule found in soy products could hold the clue to a new class of potent anti-inflammatory drugs, targeting diseases ranging from heart conditions to COVID-19.…  Read more

    Associate Professor Michael Gantier's soy-sourced anti-inflammatory research takes the STING out of disease.
  • RNA boost for autoimmune disease

    The enormous potential of RNA-based treatments for autoimmune diseases has been recognised by the Victorian government, with a new grant from the mRNA Victoria Research Acceleration Fund.…  Read more

    Associate Professor Michael Gantier has been awarded a new grant to research further into RNA-based treatments for autoimmune diseases.
  • Australian scientists find genetic cause of lupus

    An international study that found a novel genetic cause of lupus owes much of its success to a single lab in Melbourne.…  Read more

    Associate Professor Michael Gantier from the Nucleic Acids and Innate Immunity Research Group at Hudson Institute
  • Making more effective and efficient RNA therapeutics

    RNA technology developed by Hudson Institute of Medical Research with the potential to limit inflammatory side-effects of RNA therapeutics such as mRNA vaccines, is the subject of a new licensing deal.…  Read more

    Associate Professor Michael Gantier, developing RNA therapeutics subject to a new licensing deal, Noxopharm Limited.
  • Flicking the inflammation off-switch

    Many human diseases, including autoimmune diseases such as arthritis or inflammatory bowel disease, are characterised by too much inflammation.
    There has been a gap in producing new generations of potent anti-inflammatory therapeutics for these anti-inflammatory conditions.…  Read more

    A/Prof Claudia Nold and Professor Marcel Nold from The Ritchie Centre at Hudson Institute of Medical Research
  • Discovery opens up new RNA therapies for diseases driven by auto-inflammation

    RNA therapeutics comprise a rapidly expanding category of drugs that have the potential to revolutionise treatments for many diseases, including those currently deemed undruggable.…  Read more

    Dr Michael Gantier from the Nucleic Acids and Innate Immunity Research Group at Hudson Institute
  • Hyper-acute inflammation in COVID-19

    Sepsis is a hyper-acute inflammatory response leading to life-threatening organ dysfunction. Sepsis is usually caused by bacterial infections; however, the COVID-19 pandemic illustrates that hyper-acute inflammation can also be part of viral infections.…  Read more

    Dr Michael Gantier from the Nucleic Acids and Innate Immunity Research Group at Hudson Institute
  • Unearthing a new form of toxic inflammation

    Hudson Institute scientists have discovered how a molecule is transferred between damaged cells and healthy immune cells, which might cause toxic inflammation in a host of diseases.…  Read more

    Dr Michael Gantier from the Nucleic Acids and Innate Immunity Research Group at Hudson Institute
  • Paving the way towards a new anti-inflammatory agent

    Hudson Institute researchers provide new insights into how the IL-37 protein blocks inflammation—emphasising the potential for a novel treatment in the fight against a plethora of inflammatory diseases.…  Read more

    Dr Ina Rudloff, Postdoctoral Scientist in the Interventional Immunology in Early Life Diseases Research Group at Hudson Institute
  • Stunning NHMRC Grant success

    Hudson Institute has had outstanding success in the recent NHMRC Project Grant round. In addition, our researchers have been awarded an NHMRC Partnership Grant, an NHMRC Development Grant, an ARC Discovery Grant and three NMHRC Fellowships.…  Read more

    Professor Marcel Nold and A/Professor Claudia Nold from Hudson Institute of Medical Research
  • Scientists override the body’s inflammatory response

    Scientists who have discovered the mechanism of a protein that suppresses inflammation in the body, say the information could potentially be used to develop new drugs to control inflammation.…  Read more

    3D Reconstruction PBMC Shading Surface